Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
The study objective is to perform retrospective analysis of the efficacy and safety of vandetanib for metastatic and non-resectable medullary thyroid cancer in routine clinical practice. Materials and methods. We analyzed treatment outcomes in 46 patients treated with vandetanib. We also evaluated p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-07-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/526 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242533603835904 |
|---|---|
| author | I. S. Romanov А. М. Mudunov S. О. Podvyaznikov А. V. Ignatova Yu. V. Alymov |
| author_facet | I. S. Romanov А. М. Mudunov S. О. Podvyaznikov А. V. Ignatova Yu. V. Alymov |
| author_sort | I. S. Romanov |
| collection | DOAJ |
| description | The study objective is to perform retrospective analysis of the efficacy and safety of vandetanib for metastatic and non-resectable medullary thyroid cancer in routine clinical practice. Materials and methods. We analyzed treatment outcomes in 46 patients treated with vandetanib. We also evaluated progression-free survival, overall survival, time to progression, and frequency of adverse events. Results. At a median follow-up time of 27.4 months (range: 2.5–106.5 months) and median duration of vandetanib therapy of 21 months, disease progression was registered in 32.6 % of cases, whereas stable disease was observed in 28.3 % of cases and 8.7 % of study participants demonstrated partial response. One patient had complete response to treatment. Almost one-third of patients (28.2 %) died, including 2 individuals whose death was not associated with cancer. The one-year and three-year progression-free survival rates were 67.3 % and 33.3 %, respectively; the two-year and five-year overall survival rates were 82.4 % and 29.4 %, respectively. The efficacy of therapy was confirmed by a 79.4 % decrease in the serum level of calcitonin after treatment initiation. Side effects were observed in 33.9 % of patients (primarily skin and gastrointestinal toxic reactions) and were easily managed in most of the cases. Eight individuals (17.4 %) required cessation of vandetanib due to adverse events. Conclusion. Our findings suggest high efficacy and acceptable safety profile of vandetanib in the treatment of progressive locally advanced non-resectable and disseminated medullary thyroid cancer |
| format | Article |
| id | doaj-art-79c0fe15545b43b6afe1f60f1bcf8acc |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2020-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-79c0fe15545b43b6afe1f60f1bcf8acc2025-08-20T03:59:48ZrusABV-pressОпухоли головы и шеи2222-14682411-46342020-07-01102465310.17650/2222-1468-2020-10-2-46-53392Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)I. S. Romanov0А. М. Mudunov1S. О. Podvyaznikov2А. V. Ignatova3Yu. V. Alymov4N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; RUDN UniversityN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaThe study objective is to perform retrospective analysis of the efficacy and safety of vandetanib for metastatic and non-resectable medullary thyroid cancer in routine clinical practice. Materials and methods. We analyzed treatment outcomes in 46 patients treated with vandetanib. We also evaluated progression-free survival, overall survival, time to progression, and frequency of adverse events. Results. At a median follow-up time of 27.4 months (range: 2.5–106.5 months) and median duration of vandetanib therapy of 21 months, disease progression was registered in 32.6 % of cases, whereas stable disease was observed in 28.3 % of cases and 8.7 % of study participants demonstrated partial response. One patient had complete response to treatment. Almost one-third of patients (28.2 %) died, including 2 individuals whose death was not associated with cancer. The one-year and three-year progression-free survival rates were 67.3 % and 33.3 %, respectively; the two-year and five-year overall survival rates were 82.4 % and 29.4 %, respectively. The efficacy of therapy was confirmed by a 79.4 % decrease in the serum level of calcitonin after treatment initiation. Side effects were observed in 33.9 % of patients (primarily skin and gastrointestinal toxic reactions) and were easily managed in most of the cases. Eight individuals (17.4 %) required cessation of vandetanib due to adverse events. Conclusion. Our findings suggest high efficacy and acceptable safety profile of vandetanib in the treatment of progressive locally advanced non-resectable and disseminated medullary thyroid cancerhttps://ogsh.abvpress.ru/jour/article/view/526medullary thyroid cancervandetanibtyrosine kinase inhibitorssurvivaladverse events |
| spellingShingle | I. S. Romanov А. М. Mudunov S. О. Podvyaznikov А. V. Ignatova Yu. V. Alymov Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) Опухоли головы и шеи medullary thyroid cancer vandetanib tyrosine kinase inhibitors survival adverse events |
| title | Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) |
| title_full | Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) |
| title_fullStr | Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) |
| title_full_unstemmed | Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) |
| title_short | Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience) |
| title_sort | analysis of treatment outcomes in patients with progressive locally advanced non resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials russian experience |
| topic | medullary thyroid cancer vandetanib tyrosine kinase inhibitors survival adverse events |
| url | https://ogsh.abvpress.ru/jour/article/view/526 |
| work_keys_str_mv | AT isromanov analysisoftreatmentoutcomesinpatientswithprogressivelocallyadvancednonresectableanddisseminatedmedullarythyroidcancerreceivingvandetaniboutsideofclinicaltrialsrussianexperience AT ammudunov analysisoftreatmentoutcomesinpatientswithprogressivelocallyadvancednonresectableanddisseminatedmedullarythyroidcancerreceivingvandetaniboutsideofclinicaltrialsrussianexperience AT sopodvyaznikov analysisoftreatmentoutcomesinpatientswithprogressivelocallyadvancednonresectableanddisseminatedmedullarythyroidcancerreceivingvandetaniboutsideofclinicaltrialsrussianexperience AT avignatova analysisoftreatmentoutcomesinpatientswithprogressivelocallyadvancednonresectableanddisseminatedmedullarythyroidcancerreceivingvandetaniboutsideofclinicaltrialsrussianexperience AT yuvalymov analysisoftreatmentoutcomesinpatientswithprogressivelocallyadvancednonresectableanddisseminatedmedullarythyroidcancerreceivingvandetaniboutsideofclinicaltrialsrussianexperience |